Systemic epigallocatechin gallate protects against retinal degeneration and hepatic oxidative stress in the P23H-1 rat

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/117370
Información del item - Informació de l'item - Item information
Título: Systemic epigallocatechin gallate protects against retinal degeneration and hepatic oxidative stress in the P23H-1 rat
Autor/es: Perdices, Lorena | Fuentes-Broto, Lorena | Segura, Francisco | Cavero, Ana | Orduna, Elvira | Insa-Sánchez, Gema | Sánchez Cano, Ana | Fernández-Sánchez, Laura | Cuenca, Nicolás | Pinilla Lozano, Isabel
Grupo/s de investigación o GITE: Neurobiología del Sistema Visual y Terapia de Enfermedades Neurodegenerativas (NEUROVIS)
Centro, Departamento o Servicio: Universidad de Alicante. Departamento de Fisiología, Genética y Microbiología | Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía
Palabras clave: Antioxidants | Contrast sensitivity | Electroretinogram | Green tea | Neurodegeneration | Oxidative stress | Retinal degeneration | Retinitis pigmentosa | Systemic | Visual acuity
Área/s de conocimiento: Biología Celular | Farmacología
Fecha de publicación: 4-ago-2021
Editor: Wolters Kluwer - Medknow
Cita bibliográfica: Neural Regeneration Research. 2022, 17(3): 625-631. https://doi.org/10.4103/1673-5374.320990
Resumen: Retinitis pigmentosa (RP) is a group of inherited retinal disorders that lead to photoreceptor loss. RP has been reported to be related to oxidative stress, autophagy, and inflammation. (-)-Epigallocatechin gallate (EGCG), the most abundant catechin-based flavonoid in green tea leaves, has significant antioxidant, anti-carcinogenic, antimicrobial, and neuroprotective properties. EGCG, given its low molecular weight and hydrophilic properties, can cross the blood-retinal barrier and is able to reach different ocular tissues such as the lens, cornea, and retina. EGCG has been shown to provide retinal protection against ischemia; sodium nitroprusside-, N-methyl-D-aspartate-, lipopolysaccharide-, light-, sodium iodate-, or H2O2-induced damage and diabetic retinopathy. This suggests that systemic EGCG administration has the potential to protect against retinal degenerative or neurodegenerative diseases such as RP. The aim of this work was to investigate whether EGCG can protect against RP progression in the animal P23H line 1, the model of RP. Albino P23H rats were crossed with pigmented Long Evans rats to produce offspring exhibiting the clinical features of RP. Pigmented P23H rats were treated via intraperitoneal injection with saline or EGCG at a dose of 25 mg/kg every week from P100 to P160 and then compared to wild-type Long Evans rats. Rats treated with EGCG showed better visual and retinal electrical function with increased contrast sensitivity and b-wave values compared with those observed in P23H rats treated with vehicle. EGCG reduced lipid peroxidation and increased total antioxidant capacity and catalase and superoxide dismutase activities. No differences were observed in visual acuity, nitrate levels, nitrite levels or glutathione S-transferase activity. In conclusion, EGCG not only reduced the loss of visual function in P23H rats but also improved the levels of antioxidant enzymes and reduced oxidative damage. This study was approved by the Institutional Animal Care and Use Committee (CEICA) from the University of Zaragoza under project license PI12/14 on July 11, 2014.
Patrocinador/es: This study was supported by the Instituto de Salud Carlos III (project PI13/01124 and Ocular Pathology National Net RETICS-Oftared RD16/ 0008) the Fondo Europeo de Desarrollo Regional (FEDER) funds: “Una manera de hacer Europa”; and the Government of Aragon (Group B08_17R and Predoctoral Grant L. Perdices, C060/2014).
URI: http://hdl.handle.net/10045/117370
ISSN: 1673-5374 (Print) | 1876-7958 (Online)
DOI: 10.4103/1673-5374.320990
Idioma: eng
Tipo: info:eu-repo/semantics/article
Derechos: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Revisión científica: si
Versión del editor: https://doi.org/10.4103/1673-5374.320990
Aparece en las colecciones:INV - NEUROVIS - Artículos de Revistas

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
ThumbnailPerdices_etal_2022_NeuralRegenRes.pdf735,45 kBAdobe PDFAbrir Vista previa


Este ítem está licenciado bajo Licencia Creative Commons Creative Commons